Neurogene
NGNE
50 hedge funds and large institutions have $302M invested in Neurogene in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 9 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
19% more capital invested
Capital invested by funds: $253M → $302M (+$48.8M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 4.58% → 4.56% (-0.02%)
4% less funds holding
Funds holding: 52 → 50 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
45% less call options, than puts
Call options by funds: $2.33M | Put options by funds: $4.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$6.01M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.97M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.45M |
| 4 |
Morgan Stanley
New York
|
+$1.08M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$790K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$11.1M |
| 2 |
BlackRock
New York
|
-$2.95M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$2.54M |
| 4 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
-$1.56M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.04M |
NGNE Hedge Fund Activity: Q1 2018 in Review
50 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q1 2018, worth a combined $302M — up 19% from $253M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of NGNE and 7 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 21 added.
The largest buyer was Boxer Capital, adding an estimated $6.01M. The largest seller was Goldman Sachs, cutting an estimated $11.1M.
- 50 institutional investors held Neurogene (NGNE) as of Q1 2018, down from 52 in Q4 2017.
- Funds reported $302M of Neurogene stock for Q1 2018, up 19% quarter-over-quarter.
- 7 funds opened new Neurogene positions in Q1 2018 and 9 closed out, a net change of -2 holders.
- The largest Neurogene buyer in Q1 2018 was Boxer Capital, an estimated $6.01M added.
- The largest Neurogene seller in Q1 2018 was Goldman Sachs, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2018.